Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for Kura Oncology (KURA) over the last 13 years, with Dec 2024 value amounting to $15.2 million.

  • Kura Oncology's Change in Accured Expenses rose 124.03% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year change of. This contributed to the annual value of $15.2 million for FY2024, which is 47.19% up from last year.
  • According to the latest figures from FY2024, Kura Oncology's Change in Accured Expenses is $15.2 million, which was up 47.19% from $10.3 million recorded in FY2023.
  • Kura Oncology's 5-year Change in Accured Expenses high stood at $15.2 million for FY2024, and its period low was -$2.5 million during FY2021.
  • Its 3-year average for Change in Accured Expenses is $8.2 million, with a median of $10.3 million in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 144.35% in 2021, then surged by 1,387.66% in 2023.
  • Kura Oncology's Change in Accured Expenses (Yearly) stood at $5.7 million in 2020, then slumped by 144.35% to -$2.5 million in 2021, then surged by 68.15% to -$802,000 in 2022, then soared by 1,387.66% to $10.3 million in 2023, then spiked by 47.19% to $15.2 million in 2024.